Introduction of Alternative Pathway
The alternative pathway is one of three complement pathways that lead to activation of the complement cascade. The alternative pathway does not require a specific antibody to begin, so it can be much faster and more efficient than in the case where antibody synthesis is required in the classical pathway. Instead, in the alternative pathway of complement activation, the C3 protein directly binds to microorganisms and only certain types of antigens can activate this pathway. The alternative pathway can be activated by bacteria, viruses, fungi, cobra venom, parasites, IgA immune complexes and polysaccharides and form an important part of the defense mechanism independent of the immune response.
How is Complement Activated in Alternative Pathway
The AP activation occurs on microbial surfaces in the absence of specific antibody. The alternative pathway is activated slowly by the spontaneous hydrolysis of the internal C3 thioester bond and further triggered by contact with various proteins, lipids and carbohydrate structures on microorganisms and other foreign surfaces. Activation of the alternative pathway triggers a cascade involving C3 and factors B and D and properdin, result in cleavage of C5 and formation of the membrane attack complex (MAC), which in its final state creates a pore in the cell wall and causes cell lysis (Fig.1).
Fig. 1 Alternative and classic complement pathways.1
Alternative pathways of complement activation can be divided into the following phases:
Regulation of Alternative Pathway
To prevent the complement cascade being activated against the body's own cells, there are several different kinds of regulatory proteins that disrupt the complement activation process. These include serum-based and cell-based factors that inactivate C3b when it is produced (Fig.2). Serum-based factors include complement factor H and factor I. The cell-based receptors include CD46 or membrane cofactor protein (MCP) and thrombomodulin. Mutations or loss of all of these regulatory molecules can cause uncontrolled activation of the alternative pathway, which can lead to diseases such as atypical hemolytic uremic syndrome (aHUS).
Each regulatory protein can promote C3b inactivation and prevent further progression of the complement cascade. Factor H binds C3b and works with factor I to inactivate it. MCP can also bind to C3b which has become attached to cells and works with factor l to inactivate it. In addition, thrombomodulin regulates complement by inactivating the pro-inflammatory mediators C3a and C5a and accelerating factor l-mediated C3b inactivation because mutations are associated with aHUS. Thrombomodulin also plays a role in the regulation of local coagulation through interaction with thrombin.
Creative Biolabs offers a range of comprehensive complement-related products and complement testing services, including:
Complement Test Service | ||
---|---|---|
Complement Products | |||
---|---|---|---|
If you have any questions about our complement testing services and products, please feel free to contact us.
Reference
Related Product